Belite Bio (BLTE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Belite Bio (BLTE) is Neutral.

The composite score behind that read is +0.06, weighing +0.34 of bullish evidence against -0.34 bearish.

Belite Bio last closed at $156.08, +0.30% on the session.

Against the IVW growth benchmark the position is +0.46% over the forecast window.

The read is built from 12 underlying insights — 7 bullish and 5 bearish.

Agreement across those insights is 58%.

Belite Bio has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Belite Bio in the 29th percentile on return on equity, where 100 is best.

Belite Bio is classified under Health Care / Pharmaceuticals, with a market capitalisation of $6.27B.

StockMap tracks Belite Bio as the 22nd largest of the 149 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 62 Moderate Underperform, 59 Neutral, 21 Strong Underperform and 7 Moderate Outperform.

On that composite Belite Bio ranks 20th of 149 in the group, against a group median of -0.27.